$REGN REGENERON PHARMACEUTICALS, INC. Insider Trading Week 23/2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in REGENERON PHARMACEUTICALS, INC. in week 23/2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Option Exercise | M | 391.92 | 1,706 | 668,616 | 6,823 | |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Option Exercise | M | 391.92 | 1,706 | 668,616 | 8,529 | |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 625.00 | 1,706 | 1,066,250 | 643 | 2.3 K to 643 (-72.63 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Buy | M | 391.92 | 1,706 | 668,616 | 2,349 | 643 to 2.3 K (+265.32 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 616.19 | 99 | 61,003 | 643 | 742 to 643 (-13.34 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 615.28 | 80 | 49,222 | 742 | 822 to 742 (-9.73 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 613.03 | 5 | 3,065 | 822 | 827 to 822 (-0.60 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 612.52 | 265 | 162,318 | 827 | 1.1 K to 827 (-24.27 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 611.46 | 164 | 100,279 | 1,092 | 1.3 K to 1.1 K (-13.06 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 610.41 | 202 | 123,303 | 1,256 | 1.5 K to 1.3 K (-13.85 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 609.48 | 161 | 98,126 | 1,458 | 1.6 K to 1.5 K (-9.94 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 608.62 | 330 | 200,845 | 1,619 | 1.9 K to 1.6 K (-16.93 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 607.64 | 251 | 152,518 | 1,949 | 2.2 K to 1.9 K (-11.41 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Sell | S | 606.64 | 149 | 90,389 | 2,200 | 2.3 K to 2.2 K (-6.34 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Zoghbi Huda Y | Director | Buy | M | 391.92 | 1,706 | 668,616 | 2,349 | 643 to 2.3 K (+265.32 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 0 | |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 624.56 | 59 | 36,849 | 24,373 | 24.4 K to 24.4 K (-0.24 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 621.56 | 16 | 9,945 | 24,432 | 24.4 K to 24.4 K (-0.07 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 620.70 | 58 | 36,001 | 24,448 | 24.5 K to 24.4 K (-0.24 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 619.73 | 66 | 40,902 | 24,506 | 24.6 K to 24.5 K (-0.27 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 616.00 | 31 | 19,096 | 24,572 | 24.6 K to 24.6 K (-0.13 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 614.41 | 34 | 20,890 | 24,603 | 24.6 K to 24.6 K (-0.14 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 613.53 | 23 | 14,111 | 24,637 | 24.7 K to 24.6 K (-0.09 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 612.74 | 177 | 108,455 | 24,660 | 24.8 K to 24.7 K (-0.71 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 611.82 | 14 | 8,565 | 24,837 | 24.9 K to 24.8 K (-0.06 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 608.91 | 65 | 39,579 | 24,851 | 24.9 K to 24.9 K (-0.26 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 607.50 | 445 | 270,338 | 24,916 | 25.4 K to 24.9 K (-1.75 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 610.18 | 2,512 | 1,532,772 | 25,361 | 27.9 K to 25.4 K (-9.01 %) |
| Jun 12 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 27,873 | 24.4 K to 27.9 K (+14.36 %) |
| Jun 11 2020 | REGN | REGENERON PHARMACE ... | Sanofi | Sell | S | 597.48 | 120,234 | 71,837,410 | 279,766 | 400 K to 279.8 K (-30.06 %) | |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,500 | 409,050 | 3,500 | |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,250 | 613,575 | 5,000 | |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,250 | 613,575 | 7,250 | |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,500 | 681,750 | 9,500 | |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 12,000 | |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,500 | 954,450 | 15,500 | |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 610.25 | 527 | 321,602 | 24,373 | 24.9 K to 24.4 K (-2.12 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 609.53 | 681 | 415,090 | 24,900 | 25.6 K to 24.9 K (-2.66 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 608.50 | 1,511 | 919,444 | 25,581 | 27.1 K to 25.6 K (-5.58 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 607.47 | 619 | 376,024 | 27,092 | 27.7 K to 27.1 K (-2.23 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 606.79 | 353 | 214,197 | 27,711 | 28.1 K to 27.7 K (-1.26 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 605.14 | 289 | 174,885 | 28,064 | 28.4 K to 28.1 K (-1.02 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 604.14 | 50 | 30,207 | 28,353 | 28.4 K to 28.4 K (-0.18 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 603.68 | 131 | 79,082 | 28,403 | 28.5 K to 28.4 K (-0.46 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 602.38 | 110 | 66,262 | 28,534 | 28.6 K to 28.5 K (-0.38 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 592.43 | 1,086 | 643,379 | 28,644 | 29.7 K to 28.6 K (-3.65 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,500 | 409,050 | 29,730 | 28.2 K to 29.7 K (+5.31 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 592.43 | 1,630 | 965,661 | 28,230 | 29.9 K to 28.2 K (-5.46 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,250 | 613,575 | 29,860 | 27.6 K to 29.9 K (+8.15 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 592.43 | 1,630 | 965,661 | 27,610 | 29.2 K to 27.6 K (-5.57 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,250 | 613,575 | 29,240 | 27 K to 29.2 K (+8.34 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 592.40 | 1,811 | 1,072,836 | 26,990 | 28.8 K to 27 K (-6.29 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,500 | 681,750 | 28,801 | 26.3 K to 28.8 K (+9.51 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 592.43 | 2,536 | 1,502,402 | 26,301 | 28.8 K to 26.3 K (-8.79 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 28,837 | 25.3 K to 28.8 K (+13.81 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 592.43 | 2,536 | 1,502,402 | 25,337 | 27.9 K to 25.3 K (-9.10 %) |
| Jun 10 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,500 | 954,450 | 27,873 | 24.4 K to 27.9 K (+14.36 %) |